A randomised, double-blind, dose-response, placebo-controlled, multicenter, phase IIA clinical study to evaluate the efficacy and safety of topical application of G.68.y/EtOH in patients with type 1 or type 2 diabetes with infected foot ulcers.

Trial Profile

A randomised, double-blind, dose-response, placebo-controlled, multicenter, phase IIA clinical study to evaluate the efficacy and safety of topical application of G.68.y/EtOH in patients with type 1 or type 2 diabetes with infected foot ulcers.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs RLP 068 (Primary) ; Amoxicillin/clavulanic acid
  • Indications Bacterial infections; Diabetic foot ulcer; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Acronyms DANTE
  • Most Recent Events

    • 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 01 Oct 2012 Primary endpoint 'Bacteriological-response' has been met.
    • 05 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top